JP2016525114A - Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ - Google Patents

Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ Download PDF

Info

Publication number
JP2016525114A
JP2016525114A JP2016527033A JP2016527033A JP2016525114A JP 2016525114 A JP2016525114 A JP 2016525114A JP 2016527033 A JP2016527033 A JP 2016527033A JP 2016527033 A JP2016527033 A JP 2016527033A JP 2016525114 A JP2016525114 A JP 2016525114A
Authority
JP
Japan
Prior art keywords
hcv
interferon
compound
compounds
ns5a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016527033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525114A5 (https=
Inventor
アラン・シャンドン・ワン
オマール・ディ・ロペス
ヨン・トゥ
マコネン・ベレマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016525114A publication Critical patent/JP2016525114A/ja
Publication of JP2016525114A5 publication Critical patent/JP2016525114A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016527033A 2013-07-17 2014-07-15 Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ Pending JP2016525114A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847388P 2013-07-17 2013-07-17
US61/847,388 2013-07-17
PCT/US2014/046685 WO2015026454A1 (en) 2013-07-17 2014-07-15 Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus

Publications (2)

Publication Number Publication Date
JP2016525114A true JP2016525114A (ja) 2016-08-22
JP2016525114A5 JP2016525114A5 (https=) 2017-07-27

Family

ID=51293156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016527033A Pending JP2016525114A (ja) 2013-07-17 2014-07-15 Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ

Country Status (4)

Country Link
EP (1) EP3021846A1 (https=)
JP (1) JP2016525114A (https=)
CN (1) CN105555266B (https=)
WO (1) WO2015026454A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2017076187A1 (zh) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用
WO2017076194A1 (zh) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 具有抑制hcv活性的化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500413A (ja) * 2006-08-11 2010-01-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2012009394A2 (en) * 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication
WO2012166716A2 (en) * 2011-05-27 2012-12-06 Achillion Pharmaceuticals, Inc. Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US9326973B2 (en) * 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500413A (ja) * 2006-08-11 2010-01-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2012009394A2 (en) * 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication
WO2012166716A2 (en) * 2011-05-27 2012-12-06 Achillion Pharmaceuticals, Inc. Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections

Also Published As

Publication number Publication date
EP3021846A1 (en) 2016-05-25
CN105555266A (zh) 2016-05-04
CN105555266B (zh) 2018-11-30
WO2015026454A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
JP7795521B2 (ja) 抗ウイルス剤としての官能化ペプチド
EP3947368B1 (en) Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
DK2784075T3 (en) Hepatitis C viral inhibitors
JP5815746B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5529120B2 (ja) Ｃ型肝炎ウイルス阻害剤
CN103827108B (zh) 丙型肝炎病毒抑制剂
CN111433210A (zh) 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
JP2023537402A (ja) 抗ウイルス剤としての機能化ペプチド
KR20120133366A (ko) Ｃ형 간염 바이러스 억제제
KR20110134497A (ko) Ｃ형 간염 바이러스 억제제
TW200938191A (en) Hepatitis C virus inhibitors
KR20120034603A (ko) Ｃ형 간염 바이러스 억제제
KR20110124774A (ko) Ｃ형 간염 바이러스 억제제
KR20100123717A (ko) Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체
JP2012528161A (ja) Ｃ型肝炎ウイルス阻害剤
CN103608020B (zh) 核苷化合物在制备用于治疗登革热的药物中的用途
JP2014534206A (ja) Ｃ型肝炎ウイルス阻害剤
CA2914529A1 (en) Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
CN111315734B (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
JP2016525114A (ja) Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ
JP2016527232A (ja) Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
US9717712B2 (en) Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
NZ787942A (en) Nitrile-containing antiviral compounds
WO2017023631A1 (en) Hepatitis c virus inhibitors
JP2016515105A (ja) Ｃ型肝炎の処置のためのピリミジン化合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190514